PACE-AMR

Oxford Drug Design is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. The company employs advanced methodologies in computer-aided drug discovery, encompassing the entire process from target identification to preclinical studies and formulation. Its multidisciplinary research team integrates breakthroughs in computational chemistry, cheminformatics, mathematics, and cloud computing to enhance drug discovery efforts. The company's flagship platform, DrugFinder, represents a next-generation approach to identifying and developing new antibiotics, particularly targeting challenging diseases with significant unmet medical needs. By leveraging these technologies, Oxford Drug Design aims to provide healthcare professionals with effective treatment options for patients suffering from antibiotic-resistant bacterial infections.

Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.